MindMaze Therapeutics Triples Home-Based Rehab Dose Ahead of MindMotion Lite Launch

  • Multi-site program with Vibra Healthcare showed home-based rehab using MindMotion increased motor-training dose by a median factor of 3x compared to outpatient therapy alone.
  • 84% of training was completed independently without direct therapist supervision.
  • Participants showed statistically significant improvements in functional independence, balance, mobility, and cognition.
  • MindMotion Lite tablet-based solution expected to launch by year-end 2026, simplifying home deployment.

MindMaze Therapeutics is addressing a critical gap in post-clinic care for neurological patients, aligning with the 2026 AHA/ASA guidelines. The shift to home-based, high-dose rehabilitation could redefine the neurotherapeutics market, particularly as healthcare systems seek cost-effective, scalable solutions. The upcoming launch of MindMotion Lite may further solidify MindMaze's position as a leader in precision neurotherapeutics.

Adoption Pace
Whether MindMotion Lite can accelerate adoption among healthcare providers and patients.
Clinical Validation
How additional real-world evidence will impact regulatory approvals and reimbursement.
Market Expansion
The pace at which MindMaze can extend its home-based solutions to other neurological conditions.